Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arcus Biosciences (RCUS) Shares Outstanding (Weighted Average) (2017 - 2025)

Historic Shares Outstanding (Weighted Average) for Arcus Biosciences (RCUS) over the last 7 years, with Q3 2025 value amounting to $106.5 million.

  • Arcus Biosciences' Shares Outstanding (Weighted Average) rose 1652.08% to $106.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.5 million, marking a year-over-year increase of 1652.08%. This contributed to the annual value of $90.1 million for FY2024, which is 2175.68% up from last year.
  • Latest data reveals that Arcus Biosciences reported Shares Outstanding (Weighted Average) of $106.5 million as of Q3 2025, which was up 1652.08% from $106.1 million recorded in Q2 2025.
  • Arcus Biosciences' Shares Outstanding (Weighted Average)'s 5-year high stood at $106.5 million during Q3 2025, with a 5-year trough of $69.3 million in Q4 2021.
  • Over the past 5 years, Arcus Biosciences' median Shares Outstanding (Weighted Average) value was $74.3 million (recorded in 2023), while the average stood at $82.6 million.
  • Its Shares Outstanding (Weighted Average) has fluctuated over the past 5 years, first skyrocketed by 2648.96% in 2021, then surged by 194.99% in 2023.
  • Arcus Biosciences' Shares Outstanding (Weighted Average) (Quarter) stood at $69.3 million in 2021, then increased by 3.9% to $72.0 million in 2022, then rose by 2.78% to $74.0 million in 2023, then rose by 21.76% to $90.1 million in 2024, then increased by 18.2% to $106.5 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $106.5 million for Q3 2025, versus $106.1 million for Q2 2025 and $98.4 million for Q1 2025.